Project Grant R43TR005757
Award Date 8/5/26
Completion Date 8/4/27
Dollars Obligated $322K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Delaqua Pharmaceuticals, Inc. aims to enhance the therapeutic use of hydrophobic drugs through a polymeric micelle approach to drug solubilization. The key objectives are to 1) improve the formulation of spherical micelles for enhanced stability and drug solubilization, 2) perform initial toxicity studies to establish the safety of the platform, and 3) demonstrate...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded $931,463 to Acousticabio, Inc. on August 1, 2026, under SBIR Phase II funding (CFDA 93.350) to develop microgel-based formulations enabling subcutaneous delivery of monoclonal antibodies at ultra-high concentrations. Monoclonal antibodies currently require intravenous administration because their structural complexity and poor stability make high-concentration formulation difficult. IV...
- The National Center for Advancing Translational Sciences awarded Goeppert LLC, a Philadelphia-based small disadvantaged business, $350,000 on July 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop NANO-PAVE, a nanopore-based platform for assessing adeno-associated virus (AAV) capsid quality in gene therapy manufacturing. NANO-PAVE addresses a critical bottleneck in AAV clinical translation: current quality-control assays (ELISA, ddPCR, analytical...
- Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...
- The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health awarded Portal Biotechnologies $1.215 million on September 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop a high-throughput screening platform for intracellular delivery of impermeable drug molecules and molecular probes. Portal Biotechnologies is advancing its Galaxy system, a mechanoporation-based platform that uses disposable cartridges to...
- The National Cancer Institute awarded Mucommune LLC $819,464 under the Cancer Treatment Research program (CFDA 93.395) on September 12, 2025, to develop MM010, a polyethylene glycol (PEG)-based adjunctive therapy that blocks anti-PEG antibody (APA) formation and restores efficacy of repeated PEG-asparaginase dosing in acute lymphoblastic leukemia patients. Up to half of patients treated with PEG-asparaginase develop anti-PEG antibodies that eliminate the drug from circulation, trigger...
- Grant Award Summary Spectral Therapeutics, Inc. received a $322,388 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025, through July 31, 2026, to develop and validate an optical-encoded bead technology platform for large-scale molecular library generation. The project addresses a critical bottleneck in combinatorial drug discovery by creating stimulated emission-encoded beads that enable instantaneous decoding during...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded Nabgen Inc. $312,461 on August 1, 2026, under the NCATS program (CFDA 93.350) to develop an engineered, long-acting protein M derived from mycoplasma for blocking alloantibodies in patients receiving protein replacement therapy. Nabgen is engineering protein M to neutralize inhibitory antibodies that develop in response to biological drugs, particularly in treatments for lysosomal storage...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded The Broad Institute, Inc. $436,250 on May 1, 2026, under the NCATS program (CFDA 93.350) to develop and validate the RAPID (Rare Disease Analysis Through Pooled Image-Based Identification of Drugs) platform for drug repurposing in rare disorders. The Broad Institute will develop a massively parallel screening platform that integrates pooled optical variant identification,...
- The National Center for Advancing Translational Sciences awarded The Tiny Cargo Company, a for-profit small business in Roanoke, Virginia, a Cooperative Agreement totaling $985,974 on July 1, 2026, under the NCATS program (CFDA 93.350). The award funds development and scaling of Xolacta, a milk-derived extracellular vesicle (MEV) therapeutic loaded with an esterified drug compound (ACT11-4OME) designed to promote regenerative healing of the gastrointestinal tract and bone marrow following...